Swiggy shares surge nearly 8% in market debut
The Hindu
Swiggy IPO debuts with a 7.69% jump at NSE, market valuation at ₹89,549.08 crore; shares listed at ₹412 on BSE.
Shares of food delivery and quick-commerce major Swiggy were listed with a premium of nearly 8% against the issue price of ₹390 on Wednesday, November 13, 2024.
The stock is listed at ₹412, reflecting a jump of 5.64% from the issue price on the BSE. Later, it surged 7.67% to ₹419.95.
At the NSE, shares of the firm made the market debut at ₹420, a jump of 7.69%.
The company's market valuation stood at ₹89,549.08 crore during the early trade.
The ₹11,327-crore initial public offer of Swiggy was fully subscribed on the final day of the share sale on Friday, ending with 3.59 times subscription.
The initial share sale had a price range of ₹371-390 a share.
The company's IPO (Initial Public Offering) had a fresh issue of shares worth ₹4,499 crore, along with an Offer-For-Sale (OFS) of ₹6,828 crore.
SBI, HDFC Bank, and ICICI Bank named as Domestic Systemically Important Banks with updated requirements by RBI.
USDINR pair volatile near all-time low of 84.40 due to global factors, RBI intervention, and weakening Dollar Index.
Equity markets decline on weak earnings, global trends; inflation hits 14-month high, foreign funds exit, oil prices rise.
Swiggy IPO debuts with a 7.69% jump at NSE, market valuation at ₹89,549.08 crore; shares listed at ₹412 on BSE.
Shares in Samsung Electronics fell on Wednesday to their lowest level in more than four years.
Mercedes-Benz India introduces the new Mercedes-AMG C 63 S E Performance sportscar with hybrid powertrain and innovative business model.
Hyundai Motor India Ltd. reports 16% profit decline in Q3 due to market sentiments, geopolitical factors, and Red Sea crisis.
Equity market plunges over 800 points, eroding market capitalisation by ₹5.29 lakh crore amid global economic concerns.
Aurobindo Pharma's CuraTeQ Biologics receives EMA GMP certificate for biosimilars, paving way for European approvals of three products.
BCCI to withdraw insolvency plea against Byju's after Supreme Court sets aside NCLAT judgement, NCLT hearing scheduled.
Natco Pharma's Q2 profits soar 83% to ₹676.5 crore, driven by robust exports and stable domestic business.